OncoMatch/Clinical Trials/NCT07221253
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
Is NCT07221253 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Rilvegostomig and Durvalumab for biliary tract cancer.
Treatment: Rilvegostomig · Durvalumab · Gemcitabine/Cisplatin — The purpose of this study is to measure the efficacy and safety of rilvegostomig with gemcitabine plus cisplatin vs. durvalumab with gemcitabine plus cisplatin as first line treatment for patients with advanced BTC.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Cancer type
Cholangiocarcinoma
Biomarker criteria
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy
Any prior systemic therapy received for unresectable, locally advanced or metastatic BTC.
Cannot have received: immune-regulatory receptor or mechanism targeting therapy
Any prior exposure to any other therapy targeting immune-regulatory receptors or mechanisms.
Lab requirements
Blood counts
adequate bone marrow function
Kidney function
adequate organ function
Liver function
adequate organ function
Adequate bone marrow and organ function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Birmingham, Alabama
- Research Site · Phoenix, Arizona
- Research Site · Tucson, Arizona
- Research Site · Duarte, California
- Research Site · Orange, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07221253 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require CD274?
Yes, CD274 any tested is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages